

Thomas Thiele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7265682/publications.pdf>

Version: 2024-02-01

47
papers

3,759
citations

201385

27
h-index

223531

46
g-index

50
all docs

50
docs citations

50
times ranked

5455
citing authors

#	ARTICLE	IF	CITATIONS
1	Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany. <i>Lancet Regional Health - Europe</i> , 2022, 12, 100270.	3.0	33
2	Platelet size as a mirror for the immune response after SARS-CoV-2 vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 818-820.	1.9	1
3	Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT). <i>Seminars in Hematology</i> , 2022, 59, 97-107.	1.8	30
4	Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 4137-4146.	2.5	7
5	Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial. <i>Haematologica</i> , 2021, 106, 1086-1096.	1.7	11
6	Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. <i>Blood</i> , 2021, 138, 299-303.	0.6	125
7	A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. <i>Blood</i> , 2021, 137, 3656-3659.	0.6	52
8	Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. <i>New England Journal of Medicine</i> , 2021, 384, 2092-2101.	13.9	1,765
9	Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. <i>Blood</i> , 2021, 138, 1269-1277.	0.6	102
10	Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery. <i>Neurology</i> , 2021, 97, 716-719.	1.5	32
11	Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	72
12	Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. <i>International Journal of Legal Medicine</i> , 2021, 135, 2335-2345.	1.2	38
13	Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. <i>Blood</i> , 2021, 138, 2256-2268.	0.6	228
14	Vaccine-Induced Thrombocytopenia with Severe Headache. <i>New England Journal of Medicine</i> , 2021, 385, 2103-2105.	13.9	79
15	Decline in Pathogenic Antibodies over Time in VITT. <i>New England Journal of Medicine</i> , 2021, 385, 1815-1816.	13.9	56
16	Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopenia—A Case Report. <i>Vaccines</i> , 2021, 9, 1344.	2.1	26
17	Platelet Transfusion in Perioperative Medicine. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 050-061.	1.5	15
18	Function of Large and Small Platelets Differs, Depending on Extracellular Calcium Availability and Type of Inductor. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1075-1086.	1.8	8

#	ARTICLE	IF	CITATIONS
19	Large and small plateletsâ€™ (When) do they differ?. Journal of Thrombosis and Haemostasis, 2020, 18, 1256-1267.	1.9	58
20	Mean platelet volume is more important than age for defining reference intervals of platelet counts. PLoS ONE, 2019, 14, e0213658.	1.1	17
21	Role of Platelet Size Revisitedâ€™Function and Protein Composition of Large and Small Platelets. Thrombosis and Haemostasis, 2019, 119, 407-420.	1.8	41
22	Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates. Haematologica, 2019, 104, 207-214.	1.7	37
23	Preoperative platelet transfusions to reverse antiplatelet therapy for urgent nonâ€™cardiac surgery: an observational cohort study. Journal of Thrombosis and Haemostasis, 2018, 16, 709-717.	1.9	18
24	12. GerinnungsstÃ¶rungen im Rahmen des SHT. , 2018, , 209-220.		0
25	The role of social media for blood donor motivation and recruitment. Transfusion, 2018, 58, 2257-2259.	0.8	35
26	Toward the Relevance of Platelet Subpopulations for Transfusion Medicine. Frontiers in Medicine, 2018, 5, 17.	1.2	33
27	Impact of blood sample collection methods on blood protein profiling studies. Clinica Chimica Acta, 2017, 471, 128-134.	0.5	21
28	Platelet transfusion to reverse antiplatelet therapy before decompressive surgery in patients with intracranial haemorrhage. Vox Sanguinis, 2017, 112, 535-541.	0.7	15
29	Data on the impact of the blood sample collection methods on blood protein profiling studies. Data in Brief, 2017, 14, 313-319.	0.5	4
30	Transfusionâ€™transmitted <scp>CMV</scp> infectionâ€™current knowledge and future perspectives. Transfusion Medicine, 2017, 27, 238-248.	0.5	38
31	Proteomic profile of platelets during reconstitution of platelet counts after apheresis. Proteomics - Clinical Applications, 2016, 10, 831-838.	0.8	6
32	Implications of a switch to a 100% apheresis platelet supply for patients and for blood donors: a risk benefit analysis. Vox Sanguinis, 2016, 111, 350-356.	0.7	4
33	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. American Journal of Human Genetics, 2016, 99, 40-55.	2.6	82
34	The impact of noninvasive, capillary, and venous hemoglobin screening on donor deferrals and the hemoglobin content of red blood cells concentrates: a prospective study. Transfusion, 2015, 55, 2847-2854.	0.8	18
35	Tolerance of platelet concentrates treated with <scp>UVC</scp>â€™light only for pathogen reduction â€™ a phase I clinical trial. Vox Sanguinis, 2015, 109, 44-51.	0.7	24
36	Proteome Changes in Platelets After Pathogen Inactivationâ€™An Interlaboratory Consensus. Transfusion Medicine Reviews, 2014, 28, 72-83.	0.9	80

#	ARTICLE	IF	CITATIONS
37	Pooled Platelet Concentrates or Apheresis Platelets?. New England Journal of Medicine, 2013, 368, 1848-1849.	13.9	10
38	Donor Exposures in Recipients of Pooled Platelet Concentrates. New England Journal of Medicine, 2013, 368, 487-489.	13.9	29
39	Early storage lesions in apheresis platelets are induced by the activation of the integrin α IIb β 3 and focal adhesion signaling pathways. Journal of Proteomics, 2012, 76, 297-315.	1.2	34
40	Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. Journal of Thrombosis and Haemostasis, 2012, 10, 968-971.	1.9	58
41	Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion, 2011, 51, 2620-2626.	0.8	63
42	Transfusion medicine and proteomics. Alliance or coexistence?. Blood Transfusion, 2010, 8 Suppl 3, s16-25.	0.3	3
43	BLOOD COMPONENTS: A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion, 2009, 49, 2612-2624.	0.8	138
44	Proteomic characterization of freeze-dried human plasma: providing treatment of bleeding disorders without the need for a cold chain. Transfusion, 2008, 48, 2356-2363.	0.8	41
45	Proteomics of Blood-Based Therapeutics. BioDrugs, 2007, 21, 179-193.	2.2	37
46	Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion, 2007, 47, 1221-1233.	0.8	103
47	Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates. Transfusion, 2006, 46, 377-385.	0.8	32